Table 3.
Log-transformed serum PFAS concentrations and the odds ratios for a male birth, Michigan and Texas, 2005–2009
| PFAS | Unadjusted model | Adjusted modela | Sensitivity modelb | |||
|---|---|---|---|---|---|---|
| OR | (95% CI) | OR | (95% CI) | OR | (95% CI) | |
| Maternal serum (n=230) | ||||||
| PFOS | 1.23 | (0.94–1.60) | 1.16 | (0.88–1.53) | 1.19 | (0.91–1.56) |
| PFOA | 1.06 | (0.82–1.37) | 0.93 | (0.68–1.26) | 1.01 | (0.76–1.34) |
| PFNA | 1.03 | (0.80–1.34) | 0.94 | (0.70–1.26) | 0.96 | (0.72–1.28) |
| PFDA | 1.15 | (0.88–1.49) | 1.07 | (0.81–1.42) | 1.10 | (0.83–1.45) |
| FOSA | 1.01 | (0.78–1.30) | 1.07 | (0.81–1.41) | 1.05 | (0.80–1.38) |
| EtFOSAA | 1.20 | (0.92–1.57) | 1.22 | (0.92–1.60) | 1.23 | (0.93–1.62) |
| MeFOSAA | 0.95 | (0.73–1.23) | 0.98 | (0.75–1.28) | 0.97 | (0.75–1.27) |
| Paternal serum (n=227) | ||||||
| PFOS | 1.06 | (0.81–1.37) | 1.01 | (0.78–1.33) | ||
| PFOA | 0.95 | (0.73–1.23) | 0.94 | (0.72–1.23) | ||
| PFNA | 0.99 | (0.76–1.29) | 0.94 | (0.71–1.24) | ||
| PFDA | 1.05 | (0.81–1.36) | 1.02 | (0.78–1.34) | ||
| FOSA | 1.11 | (0.85–1.44) | 1.14 | (0.86–1.51) | ||
| EtFOSAA | 0.99 | (0.77–1.29) | 0.98 | (0.75–1.29) | ||
| MeFOSAA | 0.82 | (0.63–1.07) | 0.80 | (0.60–1.06) | ||
| Couple serum (n=224) | ||||||
| PFOS (maternal) | 1.24 | (0.93–1.65) | 1.13 | (0.83–1.54) | 1.17 | (0.87–1.58) |
| PFOS (paternal) | 0.98 | (0.73–1.30) | 0.98 | (0.73–1.33) | 0.97 | (0.72–1.30) |
| PFOA (maternal) | 1.08 | (0.83–1.41) | 0.91 | (0.66–1.26) | 1.01 | (0.75–1.35) |
| PFOA (paternal) | 0.92 | (0.71–1.21) | 0.95 | (0.72–1.26) | 0.93 | (0.71–1.23) |
| PFNA (maternal) | 1.06 | (0.77–1.45) | 0.92 | (0.65–1.31) | 0.96 | (0.69–1.35) |
| PFNA (paternal) | 0.96 | (0.70–1.32) | 0.99 | (0.71–1.38) | 0.97 | (0.70–1.34) |
| PFDA (maternal) | 1.18 | (0.83–1.68) | 1.03 | (0.71–1.49) | 1.07 | (0.74–1.54) |
| PFDA (paternal) | 0.95 | (0.67–1.35) | 1.01 | (0.71–1.46) | 1.00 | (0.70–1.44) |
| FOSA (maternal) | 0.86 | (0.61–1.21) | 0.89 | (0.62–1.28) | 0.87 | (0.61–1.25) |
| FOSA (paternal) | 1.24 | (0.88–1.76) | 1.23 | (0.86–1.76) | 1.24 | (0.87–1.77) |
| EtFOSAA (maternal) | 1.20 | (0.90–1.61) | 1.15 | (0.85–1.56) | 1.18 | (0.87–1.59) |
| EtFOSAA (paternal) | 0.92 | (0.69–1.23) | 0.94 | (0.70–1.27) | 0.93 | (0.69–1.25) |
| MeFOSAA (maternal) | 1.32 | (0.85–2.06) | 1.29 | (0.82–2.03) | 1.30 | (0.83–2.04) |
| MeFOSAA (paternal) | 0.65 | (0.42–1.02) | 0.66 | (0.41–1.04) | 0.64 | (0.41–1.02) |
PFAS, perfluoroalkyl and polyfluoroalkyl substance; OR, odds ratio; CI, confidence interval; PFOS, perfluorooctane sulfonic acid; PFOA, perfluorooctanoic acid; PFNA, perfluorononanoic acid; PFDA, perfluorodecanoic acid; FOSA, perfluorooctane sulfonamide; EtFOSAA, N-ethyl-perfluorooctane sulfonamidoacetic acid; MeFOSAA, N-methyl-perfluorooctane sulfonamidoacetic acid.
a
Adjusted for age, research site, household income, and maternal parity.
b
Adjusted for above except for maternal parity.